← Research hub  ·  securities

EXO.AS · Exor N.V. 68.50 EUR -2.85 (-3.99%) 2026-SEP-18 11:38 EST

My allocationNot heldas of 2026-SEP-03 · allocation page ↗
Research: QT · STK · SA1 mention
2026-APR-12 · Pieter Slegers · Compounding Quality (Substack) · Positiveinsight · read ↗ · source page ↗68.85 EUR

In short: #8, and the list's own counter-example. "An Italian holding company controlled by the Agnelli family. The Agnelli family still owns 50% of Exor. Exor invests a lot in traditional companies. Think about Ferrari, Stellantis and Philips." Top five: Ferrari 32.4%, Stellantis 11.5%, Philips 11.4%, Lingotto 11.3%, CNH 7.8%. Then the number that sits oddly on a list assembled around long-run compounding: "Since its listing in 2022, the stock compounded by 1.5% per year" — offered without comment, and without the NAV discount that is the usual argument for owning Exor. The accompanying slide puts GAV at €33.6bn: companies 77%, Lingotto (its own asset manager) 12%, others 6%, cash 5%.

In plain English

Exor is the Agnelli family's holding company — the family behind Fiat — and they still own half of it. It holds large stakes in old-economy businesses: Ferrari at 32.4% of the portfolio, Stellantis at 11.5%, Philips at 11.4%, its own asset manager Lingotto at 11.3% and the tractor maker CNH at 7.8%.

In practice a third of Exor is Ferrari. So although it looks like a diversified industrial holding, its value is driven mostly by one luxury-goods share, with the rest as ballast plus about 5% cash.

The number the post prints without softening it: since Exor listed in its current form in 2022, the shares have compounded at 1.5% a year. That makes it the clear laggard of the list, and no discount to net asset value — the usual reason to own Exor — is quoted to offset it.

SOD 68.85 EUR (open 2026-APR-10)

Nothing matches this filter.

Verbatim excerpts from the public transcripts (auto-pulled at each mention's timestamp, lightly cleaned). Timestamps link into the video; "source page" opens that commentator's full analysis at this row. Click a mention's header line to expand it (one open at a time). For personal study — not investment advice.